The other three are unannounced GPCR targets
HiGood Health aims to provide clean, credible, and easy-to-understand health information to support better conversations with your own doctor, not to replace them
We're Here To Help
[5] [6] The FLOW trial with semaglutide demonstrated significant reductions in kidney outcomes in patients with type 2 diabetes and chronic kidney disease
Use is restricted to research settings or supervised pilot programs under the guidance of licensed healthcare professionals
Extra caution is advised in people with: A history of pancreatitis Severe acidity or gastroparesis (very slow stomach emptying) Known gallstones or gallbladder disease Advanced kidney disease Significant diabetic eye disease (retinopathy) A very low BMI or a history of eating disorders Pregnancy, plans to become pregnant, or breastfeeding, since some GLP-1 medicines stay in the body for several weeks after stopping Significant depression, who should be monitored carefully Upcoming surgery, endoscopy, or a procedure needing anaesthesia or sedation, since delayed stomach emptying can raise aspiration risk and temporary stopping may be advised How GLP-1 side effects usually progress: a typical timeline Every person is different, but clinical practice and studies suggest a rough pattern [6]: First 2 to 6 weeks: nausea, early fullness, and constipation are most common
